interaction records 54 assistance programs 55 0 personal data stored

Generic competition · all medicines · read 12 November 2026

Is there a generic of Zonisamide, and who makes it?

Zonisamide appears in 2 dosage-form groups in the FDA Orange Book as of 12 November 2026, with 7 generic makers listed as marketed across them. 1 group has a brand listed as marketed and no generic listed as marketed. The data does not state why, and it does not state that one is coming. Where both are dated, the first generic approval came 5.7 years after the first brand approval. This is the Orange Book's listing, not a forecast.

Compiled and checked by Vincent Wesley Couey (ORCID 0009-0005-6869-308X) from the Orange Book data files, downloaded 12 November 2026.

Not medical advice. This page reports what the FDA's Orange Book lists, not what a pharmacy has in stock, what anything costs, or whether a generic is right for you. Ask your pharmacist or prescriber about your own medicine.
Zonisamide2 dosage-form groups in the Orange Book
7generic makers listed
  1. Zonisamide appears in 2 dosage-form groups in the FDA Orange Book as of 12 November 2026, with 7 generic makers listed as marketed across them.
  2. 1 group has a brand listed as marketed and no generic listed as marketed. The data does not state why, and it does not state that one is coming.
  3. Where both are dated, the first generic approval came 5.7 years after the first brand approval.
  4. Patents and exclusivities are shown as listed by the application holder; the Orange Book does not rule on them, and a listed patent is not a statement that a generic is blocked. This says nothing about price, supply or quality.

Capsule, Oral

Four or more generic makers listed

Brand listed as marketed: Zonegran. 7 generic makers with 21 generic products listed as marketed; the first generic approval is dated 22 December 2005.

200020052010201520202025203007brand 2000Aurobindo Pharma Ltd, first approval 22 December 2005Granules India Ltd, first approval 22 December 2005Glenmark Pharmaceuticals Inc Usa, first approval 30 January 2006Invagen Pharmaceuticals Inc, first approval 31 May 2006Bionpharma Inc, first approval 16 August 2006Zydus Lifesciences Ltd, first approval 16 October 2006Unichem Laboratories Ltd, first approval 26 January 2021data date
generic makers listed as marketed, by first approvallisted patent expiryexclusivity end
Generic maker (applicant)First approvalProducts
Aurobindo Pharma Ltd22 December 20053
Granules India Ltd22 December 20053
Glenmark Pharmaceuticals Inc Usa30 January 20063
Invagen Pharmaceuticals Inc31 May 20063
Bionpharma Inc16 August 20063
Zydus Lifesciences Ltd16 October 20063
Unichem Laboratories Ltd26 January 20213

Patents and exclusivities still listed

No unexpired patent or exclusivity is listed against the marketed brand products in this group.

Suspension, Oral

Brand listed, no generic listed as marketed

Brand listed as marketed: Zonisade. No generic is listed as marketed.

2020202520302035204001brand 2022data datePatent 11478456 listed to expire 18 August 2038Patent 12491179 listed to expire 18 August 2038Patent 12685723 listed to expire 18 August 2038Patent 11529333 listed to expire 18 August 2038
generic makers listed as marketed, by first approvallisted patent expiryexclusivity end

Patents and exclusivities still listed

  • 18 August 2038Patent 11478456
  • 18 August 2038Patent 12491179 drug product
  • 18 August 2038Patent 12685723 drug product
  • 18 August 2038Patent 11529333 drug product

US Food and Drug Administration, Orange Book data files, downloaded 12 November 2026. A listed patent is not a ruling that a generic is blocked, and no figure here says anything about price, supply or quality. Check the Orange Book.

Where can you go from this result?

Open it in the check to search another medicine, or see every brand with no generic listed. The FDA explains generic approval in how generic drugs are approved and the FDA generic drug facts, and the Orange Book itself is the FDA Orange Book. To check what is available now, ask your pharmacist, and see the FDA drug shortages page.